Here are five notes:
1. The health system will test the safety and efficacy of ReActiv8 for adult chronic low back pain treatment.
2. ReActiv8 sends mild electrical stimulation to lower back muscles’ nerves, designed to help patients regain muscle control.
3. The patients involved in the clinical study have not undergone spine surgery and may continue to use prescribed medications during the trial.
4. To qualify for the study, patients must have suffered from low back pain for a minimum of three months and not received any relief from conservative treatments.
5. The ReActiv8 system is an investigational device, currently.
More articles on devices:
Nevro, Medtronic, Abbott, Boston Scientific dominate global SCS market: 5 observations
Mazor Robotics earns CE mark for Mazor X; Medtronic to head marketing efforts
SpinalCyte receives Australian patent: 3 highlights
